CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 4 enrolled
Drug / intervention
Adderall +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03530631
NCT03530631Phase 4Completed
CompareCT.gov

Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance

University of Alabama at Birmingham·interventional·Posted May 21, 2018·Updated Dec 16, 2019

In Brief

A Phase 4 clinical trial evaluating Adderall and Placebo for Expectancy Versus Pharmacotherapy Effect of Adderall. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The purpose of this balanced-placebo design study is to pilot a larger study to further explore the current evidence that stimulant medications are not cognitive enhancers, despite this rampant belief in young adults. While the lack of cognitive enhancement from stimulant medication has been documented in prior research, this study is the first to utilize neuroimaging technology to examine brain regions activated during neurocognitive tasks when participants believe they have been administered stimulant medication or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExpectancy Versus Pharmacotherapy Effect of Adderall
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMay 21, 2018
Enrollment StartNov 10, 2018
Primary CompletionDec 18, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 8.1 years ago

Interventions

Adderalldrug

Participants will be administered Adderall

Placebodrug

Participants will be administered placebo